Alnylam Pharmaceuticals Inc.

Jul 23, 2019

Alnylam Launches ONPATTRO® (patisiran) for the Treatment of Polyneuropathy in hATTR Amyloidosis, the First-Ever RNAi Therapeutic Approved in Canada

Apr 08, 2019

Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases

Oct 03, 2018

Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Alnylam Pharmaceuticals, Inc. - ALNY

Sep 27, 2018

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alnylam Pharmaceuticals, Inc. (ALNY) and Lead Plaintiff Deadline - November 26, 2018

Sep 27, 2018

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm

Mar 21, 2018

Regeneron and Alnylam Pharmaceuticals Announce Collaboration to Discover New Treatments for Nonalcoholic Steatohepatitis (NASH)

Mar 08, 2018

Technical Perspectives on Biotech Stocks -- Alder Biopharma, Alexion Pharma, Alnylam Pharma, and Amgen

Jun 07, 2017

Stocks Under Scanner in the Biotech Space -- Paratek Pharma, Verastem, Alnylam Pharma, and Albany Molecular Research